Published in Eur J Immunol on January 01, 2003
Delineation of multiple subpopulations of natural killer cells in rhesus macaques. Immunology (2005) 1.50
The Potential of HLA-G-Bearing Extracellular Vesicles as a Future Element in HLA-G Immune Biology. Front Immunol (2016) 1.45
Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans (2013) 1.42
HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells. Proc Natl Acad Sci U S A (2004) 1.34
Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association. Cell Mol Life Sci (2010) 1.29
Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc (2009) 1.25
Mucosal memory CD8⁺ T cells are selected in the periphery by an MHC class I molecule. Nat Immunol (2011) 1.15
Soluble HLA-G: Are they clinically relevant? Semin Cancer Biol (2007) 1.15
Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands. Tissue Antigens (2008) 1.13
Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer (2008) 1.11
HLA-G and IL-10 in serum in relation to HLA-G genotype and polymorphisms. Immunogenetics (2004) 1.09
Comprehensive analysis of MHC class I genes from the U-, S-, and Z-lineages in Atlantic salmon. BMC Genomics (2010) 1.03
The role of HLA-G in human pregnancy. Reprod Biol Endocrinol (2006) 0.95
Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. Neoplasia (2006) 0.94
Role of non-classical MHC class I molecules in cancer immunosuppression. Oncoimmunology (2013) 0.92
Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape. Nat Rev Clin Oncol (2016) 0.91
Human leukocyte antigen-G (HLA-G) polymorphism and expression in breast cancer patients. PLoS One (2014) 0.90
Modulation of HLA-G expression in human neural cells after neurotropic viral infections. J Virol (2005) 0.87
HLA-G Molecules in Autoimmune Diseases and Infections. Front Immunol (2014) 0.87
Serum soluble HLA-E in melanoma: a new potential immune-related marker in cancer. PLoS One (2011) 0.86
A novel mechanism of soluble HLA-G mediated immune modulation: downregulation of T cell chemokine receptor expression and impairment of chemotaxis. PLoS One (2010) 0.86
Amniotic fluid soluble human leukocyte antigen-G in term and preterm parturition, and intra-amniotic infection/inflammation. J Matern Fetal Neonatal Med (2009) 0.86
Soluble human leucocyte antigen-G molecules in peripheral blood haematopoietic stem cell transplantation: a specific role to prevent acute graft-versus-host disease and a link with regulatory T cells. Clin Exp Immunol (2008) 0.85
HLA-G as a tolerogenic molecule in transplantation and pregnancy. J Immunol Res (2014) 0.85
Disturbances in placental immunology: ready for therapeutic interventions? Springer Semin Immunopathol (2006) 0.85
HLA-G is found in lipid rafts and can act as a signaling molecule. Hum Immunol (2006) 0.82
HLA-G expression is an independent predictor for improved survival in high grade ovarian carcinomas. J Immunol Res (2014) 0.82
HLA-dependent tumour development: a role for tumour associate macrophages? J Transl Med (2013) 0.82
Characterization of a nonclassical class I MHC gene in a reptile, the Galápagos marine iguana (Amblyrhynchus cristatus). PLoS One (2008) 0.82
Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma. Oncoimmunology (2015) 0.81
Lymphocyte cell-cycle inhibition by HLA-G is mediated by phosphatase SHP-2 and acts on the mTOR pathway. PLoS One (2011) 0.81
Some basic aspects of HLA-G biology. J Immunol Res (2014) 0.80
HLA class Ib in pregnancy and pregnancy-related disorders. Immunogenetics (2017) 0.79
HLA-G expression in cancers: roles in immune evasion, metastasis and target for therapy. Mol Med (2015) 0.79
Human leukocyte antigen-G expression in differentiated human airway epithelial cells: lack of modulation by Th2-associated cytokines. Respir Res (2013) 0.79
Increased human leukocyte antigen-G expression at the maternal-fetal interface is associated with preterm birth. J Matern Fetal Neonatal Med (2014) 0.78
Identification of novel microRNAs regulating HLA-G expression and investigating their clinical relevance in renal cell carcinoma. Oncotarget (2016) 0.78
A new era in reproductive medicine: consequences of third-party oocyte donation for maternal and fetal health. Semin Immunopathol (2016) 0.77
Frequency of null allele of Human Leukocyte Antigen-G (HLA-G) locus in subjects to recurrent miscarriage. Int J Reprod Biomed (Yazd) (2016) 0.77
Association of serum soluble human leukocyte antigen-G levels with chronic hepatitis B virus infection. Clin Exp Med (2012) 0.76
Analysis of immunoglobulin-like transcripts (ILTs) in lymphocytes with sHLA-G and IL10 from SLE patients. Clin Exp Med (2012) 0.76
HLA-G Expression Pattern: Reliable Assessment for Pregnancy Outcome Prediction. Adv Pharm Bull (2013) 0.75
Recombinant HLA-G as Tolerogenic Immunomodulant in Experimental Small Bowel Transplantation. PLoS One (2016) 0.75
Association of soluble HLA-G with acute rejection episodes and early development of bronchiolitis obliterans in lung transplantation. PLoS One (2014) 0.75
Human Leukocyte Antigen (HLA) and Immune Regulation: How Do Classical and Non-Classical HLA Alleles Modulate Immune Response to Human Immunodeficiency Virus and Hepatitis C Virus Infections? Front Immunol (2017) 0.75
Genetic polymorphism in HLA-G 3'UTR 14-bp ins/del and risk of cancer: a meta-analysis of case-control study. Mol Genet Genomics (2015) 0.75
Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy. Clin Exp Med (2015) 0.75
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res (2009) 3.30
Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: Implications for inflammatory processes. Proc Natl Acad Sci U S A (2004) 3.05
Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol (2005) 2.34
Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica (2007) 2.30
The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol (2003) 2.29
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother (2009) 2.25
Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med (2008) 2.22
NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood (2005) 2.15
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol (2010) 2.12
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol (2009) 2.12
Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12
For breast cancer prognosis, immunoglobulin kappa chain surfaces to the top. Clin Cancer Res (2012) 2.09
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest (2009) 2.08
Lost in Translation: Obstacles to Translational Medicine. J Transl Med (2004) 2.03
HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res (2008) 1.77
Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. Clin Immunol (2011) 1.69
Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol (2004) 1.68
Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res (2005) 1.68
Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol (2003) 1.67
HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res (2006) 1.65
Monoclonal antibodies for cancer immunotherapy. Lancet (2009) 1.64
Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res (2013) 1.63
Fingolimod modulates peripheral effector and regulatory T cells in MS patients. J Neuroimmune Pharmacol (2013) 1.59
Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia (2004) 1.56
Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol (2003) 1.55
Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8⁺ T cells. Clin Cancer Res (2011) 1.54
Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol (2006) 1.49
Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol (2003) 1.49
Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget (2014) 1.49
Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma. J Invest Dermatol (2005) 1.48
Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res (2006) 1.48
Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother (2007) 1.47
A novel Bim-BH3-derived Bcl-XL inhibitor: biochemical characterization, in vitro, in vivo and ex-vivo anti-leukemic activity. Cell Cycle (2008) 1.45
Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res (2006) 1.45
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck (2010) 1.45
Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity. Cancer Res (2006) 1.43
Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt. Cell Cycle (2012) 1.41
Polyclonality of BRAF mutations in acquired melanocytic nevi. J Natl Cancer Inst (2009) 1.40
HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol (2002) 1.39
A case of transposition of the great arteries in a female infant of a HIV-1-infected woman. Potential teratogenic effects of antiretroviral drugs. Intern Emerg Med (2006) 1.39
Migraine during systemic lupus erythematosus: findings from brain single photon emission computed tomography. J Rheumatol (2006) 1.39
Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res (2010) 1.37
Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer (2013) 1.35
HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res (2005) 1.35
Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res (2007) 1.35
CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol (2007) 1.35
Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function. Hum Immunol (2004) 1.32
Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res (2005) 1.32
Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer (2006) 1.32
Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE. PLoS One (2009) 1.30
Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells (2008) 1.28
Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res (2005) 1.27
Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res (2011) 1.26
Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events. Autoimmun Rev (2011) 1.26
CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J Natl Cancer Inst (2010) 1.26
Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. Surgery (2006) 1.25
A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. J Immunol Methods (2005) 1.25
Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res (2005) 1.25
Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol (2002) 1.23
Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther (2008) 1.23
Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J Immunol (2005) 1.23
HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin Cancer Res (2005) 1.22
Current views on diagnostic approach and treatment of lymphedema. Am J Med (2012) 1.21
Vdelta1 T lymphocytes producing IFN-gamma and IL-17 are expanded in HIV-1-infected patients and respond to Candida albicans. Blood (2009) 1.19
Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother (2006) 1.19
Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J Cell Biol (2004) 1.18
Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res (2007) 1.18
SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells. Clin Cancer Res (2013) 1.18
Mechanisms of immune evasion of human neuroblastoma. Cancer Lett (2005) 1.17
HLA-G and MIC expression in tumors and their role in anti-tumor immunity. Trends Immunol (2003) 1.17
Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int J Cancer (2010) 1.16
Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions. Adv Cancer Res (2005) 1.15
Soluble HLA-G: Are they clinically relevant? Semin Cancer Biol (2007) 1.15
The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases. Intern Emerg Med (2011) 1.15
Comparative analysis of DNA repair in stem and nonstem glioma cell cultures. Mol Cancer Res (2009) 1.13
Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene (2005) 1.13
Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. Eur Respir J (2013) 1.12
Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells. Breast Cancer Res (2011) 1.11
Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res (2008) 1.11
Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes. Cancer Immunol Immunother (2011) 1.11
The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. J Biol Chem (2012) 1.11
Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood (2003) 1.10
Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells. Cancer Immunol Immunother (2008) 1.10
Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? J Urol (2004) 1.10
Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis (2012) 1.10
Extracellular DNA in biofilms. Int J Artif Organs (2011) 1.10
CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. Pigment Cell Melanoma Res (2011) 1.09
Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin Cancer Res (2009) 1.09
The complex role of B7 molecules in tumor immunology. Trends Mol Med (2008) 1.09
Human high molecular weight-melanoma-associated antigen: utility for detection of metastatic melanoma in sentinel lymph nodes. Clin Cancer Res (2008) 1.09